- Monoclonal Antibodies (mAb)
- Granulocyte Colony Stimulating Factors (G-CSF)
- Hematopoietic Agents
Europe Oncology Biosimilars market size was valued at USD 6,953.2 million in 2023 and is expected to grow at a CAGR of 19.2% during the forecast period 2024 to 2030. The European market provides a detailed overview of the Europe Oncology Biosimilars market, and that can be segmented by drug class, by cancer type, and by indication. By drug class, The Europe Oncology Biosimilars market has been segmented into Monoclonal Antibodies (mAb), Granulocyte Colony Stimulating Factors (G-CSF) and Hematopoietic Agents. The Monoclonal Antibodies (mAb) segment is likely to be the largest and fastest-growing segment in terms of drug class. Monoclonal antibodies and Insulin are seen to be the foremost segments regarding the growth rate during the forecast period because of extensive applications of monoclonal antibodies in the treatment of autoimmune disorders, cancer, and osteoporosis, and growing incidents of insulin dependent diabetes worldwide and growing demand for lucrative treatment options. Based on the Cancer type, the Europe Oncology Biosimilars market is segmented into Blood Cancer, Breast Cancer and Others Among these, the Breast Cancer segment is expected to have a significant growing market during the forecast period 2022-2028. The accessibility of biosimilars in the field of oncology has dropped prices and made cancer treatment more accessible and affordable. Also, due to the increasing prevalence of cancer, healthcare systems around the world are focusing on dropping the burden of cancer by accepting cost effective treatment choices. Based on the Indication, the Europe Oncology Biosimilars market is segmented into Malignant Lymphoma or Multiple Myeloma, HER2 Positive Metastatic Breast Cancer (MBC), Neutropenia, and Non-Hodgkin’s Lymphoma (NHL). The Metastatic Breast Cancer (MBC), segment accounts for the significant share in 2021. Based on the distribution channel, the Europe Oncology Biosimilars market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment accounts for the significant share in 2021.
In April 2021, Mylan (now Viatris) launched Abevmy a biosimilar for oncology In March 2021, mAbxience Research launched Alymsys, a biosimilar for various types of cancer
Europe Oncology Biosimilars market is chiefly driven by the cost-effectiveness and increasing demand for biosimilars
The Europe Oncology Biosimilars Market market size was valued at USD 6,953.2 million in 2023 and is expected to grow at a CAGR of 19.2% during the forecast period 2024 to 2030.
The key players of are europe oncology biosimilars market Sandoz International GmbH (Germany), Amgen Inc. (U.S.), Celltrion Healthcare Co., Ltd. (South Korea), Samsung Bioepis (South Korea)